Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 4, 2026, 12:18 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 121–144 of 250 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: Polymorphism Clear all

Conditions: Premature Birth
Interventions: Blood spot specimens will be drawn; Genetic
Lead sponsor: University of Miami; Other
Eligibility: 1 Minute to 28 Days
Enrollment: 258 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2009
U.S. locations: 2
States / cities: Fort Lauderdale, Florida

Conditions: Coronary Artery Disease
Interventions: Clopidogrel; Drug
Lead sponsor: Scripps Health; Other
Eligibility: 18 Years to 85 Years
Enrollment: 41 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2010
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Glucose Homeostasis, Protein Metabolism, Lipid Metabolism, Respiratory Function, Connective Tissue Metabolism
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: 18 Years to 100 Years
Enrollment: 278 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2019
U.S. locations: 1
States / cities: Research Triangle Park, North Carolina

Conditions: Alzheimer Disease
Interventions: Pleiotropic info, in-person disclosure, AD-only info, in-person disclosure, Pleiotropic info, phone disclosure, AD-only info, phone disclosure; Behavioral
Lead sponsor: Brigham and Women's Hospital; Other
Eligibility: 18 Years to 85 Years
Enrollment: 290 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2009
U.S. locations: 4
States / cities: Washington D.C., District of Columbia • Boston, Massachusetts • Ann Arbor, Michigan + 1 more

Conditions: Ovarian Cancer
Interventions: Vitamin D3; Drug
Lead sponsor: University of Oklahoma; Other
Eligibility: 18 Years to 99 Years · Female only
Enrollment: 81 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2020
U.S. locations: 1
States / cities: Oklahoma City, Oklahoma

Conditions: Cardiovascular Disease
Interventions: Losartan; Drug
Lead sponsor: National Heart, Lung, and Blood Institute (NHLBI); NIH
Eligibility: Not listed
Enrollment: 200 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 1997 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Dementia, Movement Disorder
Interventions: Not listed
Lead sponsor: National Institute on Aging (NIA); NIH
Eligibility: 18 Years to 120 Years
Enrollment: 12,000 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2059
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: ALS
Interventions: Not listed
Lead sponsor: National Institute of Environmental Health Sciences (NIEHS); NIH
Eligibility: Not listed
Enrollment: 397 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2003 – 2019
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: End Stage Renal Disease (ESRD)
Interventions: Not listed
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 21 Years and older
Enrollment: 2,860 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2012
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Macular Degeneration
Interventions: Not listed
Lead sponsor: National Eye Institute (NEI); NIH
Eligibility: 50 Years and older
Enrollment: 477 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2003 – 2015
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Movement Disorders
Interventions: MRI; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: Bethesda, Maryland • Providence, Rhode Island

Conditions: Lung Cancer
Interventions: Questionnaire; Behavioral
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 235 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2017
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Arteriovenous Malformations, Intracranial Aneurysm, Subarachnoid Hemorrhage
Interventions: Not listed
Lead sponsor: State University of New York - Upstate Medical University; Other
Eligibility: 18 Years to 89 Years
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2011
U.S. locations: 1
States / cities: Syracuse, New York

Conditions: Hepatitis C
Interventions: Peginterferon alfa-2a, Ribavirin, telaprevir; Drug
Lead sponsor: University of Vermont; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011
U.S. locations: 2
States / cities: Atlanta, Georgia • Burlington, Vermont

Conditions: Breast Cancer, Postmenopausal
Interventions: Dual x-ray absorptiometry (DXA), Blood draw, Questionnaire; Procedure · Behavioral
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 40 Years and older · Female only
Enrollment: 151 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2006 – 2009
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Drug Abuse
Interventions: Not listed
Lead sponsor: National Institute on Drug Abuse (NIDA); NIH
Eligibility: 18 Years to 50 Years
Enrollment: 221 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2005 – 2013
U.S. locations: 1
States / cities: Baltimore, Maryland

Conditions: Catecholaminergic Polymorphic Ventricular Tachycardia
Interventions: SGT-501; Drug
Lead sponsor: Solid Biosciences Inc.; Industry
Eligibility: 7 Years and older
Enrollment: 18 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2031
U.S. locations: 4
States / cities: Boston, Massachusetts • Rochester, Minnesota • Cleveland, Ohio + 1 more

Conditions: Breast Cancer
Interventions: Raloxifene - Usual, Raloxifene - Study; Drug
Lead sponsor: Han Xu, M.D., Ph.D., FAPCR, Sponsor-Investigator, IRB Chair; Industry
Eligibility: 24 Years to 64 Years · Female only
Enrollment: 600 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2026
U.S. locations: 1
States / cities: Rockville, Maryland

Conditions: Neoplasms, Lymphomas
Interventions: Belinostat; Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years to 110 Years
Enrollment: 72 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 7
States / cities: Davis, California • Duarte, California • Los Angeles, California + 4 more

Conditions: Non-alcoholic Fatty Liver Disease
Interventions: Not listed
Lead sponsor: UNC Nutrition Research Institute; Other
Eligibility: 18 Years to 70 Years
Enrollment: 53 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014
U.S. locations: 1
States / cities: Kannapolis, North Carolina

Conditions: Alcohol Drinking
Interventions: Alcohol (Oral), Alcohol (IV), Alcohol (Ethanol); Drug
Lead sponsor: National Institute on Alcohol Abuse and Alcoholism (NIAAA); NIH
Eligibility: 21 Years to 60 Years
Enrollment: 128 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Adverse Drug Events, Adverse Drug Reactions, Drug Interaction Potentiation, Drug Metabolism, Poor, CYP2D6-RELATED, Drug Metabolism, Poor, CYP2C19-RELATED, Cytochrome P450 Enzyme Deficiency, Cytochrome P450 CYP2D6 Enzyme Deficiency, Cytochrome P450 CYP2C9 Enzyme Deficiency, Cytochrome P450 CYP2C19 Enzyme Deficiency, Cytochrome P450 CYP3A Enzyme Deficiency, Poor Metabolizer Due to Cytochrome P450 CYP2C9 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2C19 Variant, Poor Metabolizer Due to Cytochrome P450 CYP2D6 Variant
Interventions: Not listed
Lead sponsor: Genelex Corporation; Industry
Eligibility: 65 Years and older
Enrollment: 800 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 7
States / cities: Garden Grove, California • Denver, Colorado • Lexington, Kentucky + 3 more

Conditions: Obesity
Interventions: Propofol and Fentanyl administration; Drug
Lead sponsor: Stanford University; Other
Eligibility: 18 Years to 70 Years
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2011 – 2017
U.S. locations: 1
States / cities: Stanford, California

Conditions: Diabetes Mellitus, Healthy
Interventions: Not listed
Lead sponsor: National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK); NIH
Eligibility: Not listed
Healthy volunteers: Accepts healthy volunteers
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Bethesda, Maryland

Search by objective public record fields.

Three Interacting Single Nucleotide Polymorphisms (SNPs) and the Risk of Preterm Birth in Black Families

Pilot Study on the Effect of High Clopidogrel Maintenance Dosing

The Role of Glucocorticoid Receptor SNPs in Receptor Function and Metabolic Disease

REVEAL III: Risk Evaluation and Education for Alzheimer's Disease

Vitamin D, Leptin, Vitamin D Receptor Polymorphism, and Treatment-Related Morbidity in Ovarian Cancer

Study of Inherited Changes of Receptors Located on Blood Vessels

Genetic Characterization of Movement Disorders and Dementias

Exposure to Neurotoxins as Risk Factors for ALS

Mapping of End Stage Renal Disease Genetic Susceptibility in African Americans by Admixture Linkage Disequilibrium

Genetic Factors in Age-Related Macular Degeneration

Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

Gene Polymorphisms and Symptoms in Lung Cancer Patients

Genome-wide Analysis of Single Nucleotide Polymorphisms of Brain Arteriovenous Malformations and Cerebral Aneurysm

Peginterferon and Ribavirin, With or Without Telaprevir, for Genotype 1 Hepatitis C and IL28B CC Polymorphism

Effect of Aromatase Inhibitors on Bones and Genes

Effect of Functional Genetic Polymorphisms on Brain Morphology and Function

A Study of SGT-501 Gene Therapy in Catecholaminergic Polymorphic Ventricular Tachycardia (CPVT)

Bioequivalence ANDA SNP Clinical Study - Raloxifene and Single Nucleotide Polymorphisms

Belinostat for Solid Tumors and Lymphomas in Patients With Varying Degrees of Hepatic Dysfunction

Utilizing Non-Invasive Fibroscan® Technology to Identify Genetic Markers for Fatty Liver Progression

Nicotinic Receptor Genetic Variation and Alcohol Reward

YouScript IMPACT Registry

Adiponectin Polymorphisms, Insulin Resistance, and Pharmacokinetics in Obesity

Genetic Influence on Susceptibility to Type 1 Diabetes Mellitus